收费全文 | 61850篇 |
免费 | 8529篇 |
国内免费 | 1437篇 |
耳鼻咽喉 | 503篇 |
儿科学 | 1386篇 |
妇产科学 | 1389篇 |
基础医学 | 3084篇 |
口腔科学 | 2566篇 |
临床医学 | 9122篇 |
内科学 | 7565篇 |
皮肤病学 | 879篇 |
神经病学 | 3005篇 |
特种医学 | 856篇 |
外国民族医学 | 9篇 |
外科学 | 8179篇 |
综合类 | 9646篇 |
现状与发展 | 7篇 |
一般理论 | 29篇 |
预防医学 | 6287篇 |
眼科学 | 865篇 |
药学 | 7062篇 |
480篇 | |
中国医学 | 5164篇 |
肿瘤学 | 3733篇 |
2024年 | 211篇 |
2023年 | 1721篇 |
2022年 | 2074篇 |
2021年 | 4136篇 |
2020年 | 4429篇 |
2019年 | 3554篇 |
2018年 | 3358篇 |
2017年 | 3557篇 |
2016年 | 3348篇 |
2015年 | 2868篇 |
2014年 | 4800篇 |
2013年 | 5340篇 |
2012年 | 3844篇 |
2011年 | 3973篇 |
2010年 | 2998篇 |
2009年 | 2744篇 |
2008年 | 2601篇 |
2007年 | 2621篇 |
2006年 | 2226篇 |
2005年 | 1821篇 |
2004年 | 1568篇 |
2003年 | 1382篇 |
2002年 | 1100篇 |
2001年 | 886篇 |
2000年 | 693篇 |
1999年 | 546篇 |
1998年 | 478篇 |
1997年 | 427篇 |
1996年 | 361篇 |
1995年 | 280篇 |
1994年 | 274篇 |
1993年 | 180篇 |
1992年 | 204篇 |
1991年 | 167篇 |
1990年 | 145篇 |
1989年 | 144篇 |
1988年 | 131篇 |
1987年 | 113篇 |
1986年 | 76篇 |
1985年 | 89篇 |
1984年 | 72篇 |
1983年 | 42篇 |
1982年 | 47篇 |
1981年 | 38篇 |
1980年 | 34篇 |
1979年 | 24篇 |
1978年 | 12篇 |
1977年 | 17篇 |
1976年 | 17篇 |
1975年 | 19篇 |
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献
Areas covered: We report on medication use research and have conducted a systematic review of observational studies on medication use to provide an updated overview on characteristics, objectives, methods, and patterns in hospitalized neonates. Moreover, a review on aspects of medication use for opioids, anti-epileptics, gastric acid-related disorders and respiratory stimulants with emphasis on trends and impact of interventions is presented, illustrating how research on medication use can contribute to improved neonatal pharmacotherapy and more focused research. Medication use reports describe patterns and provide signals on irrational use, benchmarking, or can guide research priorities. Moreover, this may generate information on how neonatal health topics and their pharmacotherapy are handled over time or across regions.
Expert opinion: Research on medicine utilization is relevant, since it will inform us on aspects like trends, variability, or about the impact and pattern of implementation of guidelines in neonates. Further progress necessitates to merge datasets on medication use with clinical characteristics, and perinatal drug use remains an area in need of additional research. 相似文献